(Q45887988)

17 December 2017

title

Successful use of protease inhibitors in HIV-infected haemophilia patients (English)

1 reference

17 December 2017

0 references

Merry C

1

1 reference

17 December 2017

McMahon C

2

1 reference

17 December 2017

Ryan M

3

1 reference

17 December 2017

O'Shea E

4

1 reference

17 December 2017

Mulcahy F

5

1 reference

17 December 2017

Smith OP

6

1 reference

17 December 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

17 December 2017

British Journal of Haematology

published in

1 reference

17 December 2017

volume

101

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

475-479

1 reference

17 December 2017

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

The HIV-1 protease as a therapeutic target for AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

Life expectancy of Swedish haemophiliacs, 1831-1980.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

Morbidity and mortality from transfusion-transmitted disease in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag System

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

HIV viral load markers in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

HTLV-III seroconversion associated with heat-treated factor VIII concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

Hepatitis E in Portuguese haemophiliacs and blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1998.00734.X

10.1046/J.1365-2141.1998.00734.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017